| Hans-Günter Meyer-Thompson | HIV
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Gallant, Joel et al.
The Lancet , Volume 0 , Issue 0 , Published: 31 August 2017, doi.org/10.1016/S0140-6736(17)32299-7
Abstract
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32299-7/fulltext